ACELRX PHARMACEUT. DL-01 Tangible Net Worth Ratio
ACELRX PHARMACEUT. DL-01 tangible net worth ratio. ACELRX PHARMACEUT. DL-01 (R5XA) has a Tangible Net Worth Ratio of 48.2% as of December 2025. This metric is calculated by deducting intangible assets (€8.82 Million) from net assets (€17.04 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See ACELRX PHARMACEUT. DL-01 (R5XA) balance sheet quality index to measure how much of total assets are equity-financed.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of ACELRX PHARMACEUT. DL-01 (2022–2025)
Tangible net worth ratio of ACELRX PHARMACEUT. DL-01 from 2022 to 2025. This chart shows how ACELRX PHARMACEUT. DL-01's Tangible Net Worth Ratio has changed across 4 annual periods from 2022 to 2025. As of December 2025, the ratio stands at 48.2%, reflecting net assets of €17.04 Million with intangible assets of €8.82 Million EUR. See ACELRX PHARMACEUT. DL-01 short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
ACELRX PHARMACEUT. DL-01 Tangible Net Worth Ratio by Year (2022–2025)
ACELRX PHARMACEUT. DL-01 tangible net worth ratio by year from 2022 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for ACELRX PHARMACEUT. DL-01 from 2022 to 2025, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see R5XA market cap.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 48.2% | €17.04 Million | €8.82 Million | €29.72 Million | ▲ +58.5 pp |
| 2024 | -10.2% | €8.00 Million | €8.82 Million | €18.24 Million | ▼ -47.7 pp |
| 2023 | 37.5% | €14.11 Million | €8.82 Million | €20.39 Million | ▼ -22.1 pp |
| 2022 | 59.6% | €21.81 Million | €8.82 Million | €47.49 Million | — |